Form 4: Director Granted RSUs by Cue Biopharma

Viola Mong Meehan, a Director at Cue Biopharma, Inc., was granted 21,800 Restricted Stock Units (RSUs) on July 9, 2026.

Summary

• Viola Mong Meehan, a Director of Cue Biopharma, Inc., received a grant of 21,800 Restricted Stock Units (RSUs) on July 9, 2026.
• These RSUs will vest in three equal tranches on July 9, 2027, July 9, 2028, and July 9, 2029.
• Vesting is contingent upon Ms. Meehan's continued service to the company through each respective vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation grant for a director rather than a significant financial event for the company or a change in strategic direction.

Positives

• Grant of RSUs indicates a long-term incentive for continued service and alignment with company performance.
• The grant of 21,800 RSUs suggests confidence in the company's future prospects by management/board.

Risks

• Vesting is subject to continued service, meaning the reporting person could forfeit unvested RSUs if employment or service is terminated before vesting dates.
• The value of the RSUs is tied to the future stock price of Cue Biopharma, which is subject to market volatility and company performance.

Future Outlook

The vesting schedule of the RSUs, extending over three years, implies a forward-looking expectation of continued service and company growth.

Industry Context

StockSavvy.ai notes that the grant of RSUs is a common practice in the biopharmaceutical industry for retaining key talent and aligning executive interests with long-term shareholder value, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The RSU grant represents a form of compensation, which can dilute ownership slightly over time as shares vest. However, it also aligns director incentives with long-term shareholder value.
• Employees: The grant is specific to the director and does not directly impact other employees, though it reflects the company's compensation philosophy.
• Management: The grant reinforces the importance of retaining experienced leadership like Viola Mong Meehan.

Next Steps

• Continued service by Viola Mong Meehan through the respective vesting dates (July 9, 2027, July 9, 2028, and July 9, 2029) to receive the vested shares.
• Monitoring of Cue Biopharma's stock performance and corporate developments impacting the value of the RSUs.

Key Dates

Keywords

Cue Biopharma, CUE, Form 4, Restricted Stock Units, RSU, Director, Stock Grant, Executive Compensation, Insider Trading